Chemically generated IgG2 bispecific antibodies through disulfide bridging

Bioorganic and Medicinal Chemistry Letters

Volumn 27, Issue 16, 2017, Pages 3647-3652

  Patterson, James T ^a   Gros, Edwige ^a   Zhou, Heyue ^a   Atassi, Ghazi ^a   Kerwin, Lisa ^a   Carmody, Lisa ^a   Zhu, Tong ^a   Jones, Bryan ^a   Fu, Yanwen ^a   Kaufmann, Gunnar F ^a  

^a SORRENTO THERAPEUTICS   (United States)

Author keywords

Bioconjugation; Bispecific antibody; Click chemistry; Disulfide bridging; IgG2

Indexed keywords

BISPECIFIC ANTIBODY; DISULFIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G;

ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; DISULFIDE BOND; DRUG CONJUGATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY REACTION; CHEMISTRY; CLICK CHEMISTRY; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOLOGY; MCF-7 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIGEN-ANTIBODY REACTIONS; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; CLICK CHEMISTRY; DISULFIDES; HUMANS; IMMUNOGLOBULIN G; MCF-7 CELLS; MICROSCOPY, FLUORESCENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 85023644878     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2017.07.021     Document Type: Article

References (28)

1. Kontermann, R.E., Dual targeting strategies with bispecific antibodies. MAbs 4 (2012), 182–197.
2. Spiess, C., Zhai, Q., Carter, P.J., Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67:2 Pt A (2015), 95–106.
3. Roopenian, D.C., Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7 (2007), 715–725.
4. Ridgway, J.B., Presta, L.G., Carter, P., ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9 (1996), 617–621.
5. Atwell, S., Ridgway, J.B., Wells, J.A., Carter, P., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 270 (1997), 26–35.
6. Labrijn, A.F., Meesters, J.I., de Goeij, B.E., et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 110 (2013), 5145–5150.
7. Schaefer, W., Regula, J.T., Bahner, M., et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108 (2011), 11187–11192.
8. Wu, C., Ying, H., Grinnell, C., et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25 (2007), 1290–1297.
9. Coloma, M.J., Morrison, S.L., Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15 (1997), 159–163.
10. Riethmuller, G., Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun, 12, 2012, 12.
11. Anderson, P.M., Crist, W., Hasz, D., Carroll, A.J., Myers, D.E., Uckun, F.M., G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 80 (1992), 2826–2834.
12. Reusch, U., Sundaram, M., Davol, P.A., et al. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12 (2006), 183–190.
13. Scheer, J.M., Sandoval, W., Elliott, J.M., et al. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PLoS One, 7, 2012, e51817.
14. Hudak, J.E., Barfield, R.M., de Hart, G.W., et al. Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag. Angew Chem Int Ed Engl 51 (2012), 4161–4165.
15. Kim, C.H., Axup, J.Y., Dubrovska, A., et al. Synthesis of bispecific antibodies using genetically encoded unnatural amino acids. J Am Chem Soc 134 (2012), 9918–9921.
16. Walseng, E., Nelson, C.G., Qi, J., et al. Chemically programmed bispecific antibodies in diabody format. J Biol Chem 291 (2016), 19661–19673.
17. Cao, Y., Axup, J.Y., Ma, J.S., et al. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Angew Chem Int Ed Engl 54 (2015), 7022–7027.
18. Brennan, M., Davison, P.F., Paulus, H., Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229 (1985), 81–83.
19. Glennie, M.J., McBride, H.M., Worth, A.T., Stevenson, G.T., Preparation and performance of bispecific F(ab′ gamma)2 antibody containing thioether-linked Fab′ gamma fragments. J Immunol 139 (1987), 2367–2375.
20. Patke, S., Li, J., Wang, P., et al. BisFabs: tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies. MAbs 9 (2017), 430–437.
21. Hull, E.A., Livanos, M., Miranda, E., Smith, M.E., Chester, K.A., Baker, J.R., Homogeneous bispecifics by disulfide bridging. Bioconjug Chem 25 (2014), 1395–1401.
22. Wiggins, B., Liu-Shin, L., Yamaguchi, H., Ratnaswamy, G., Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. J Pharm Sci 104 (2015), 1362–1372.
23. Liu, H., Chumsae, C., Gaza-Bulseco, G., Hurkmans, K., Radziejewski, C.H., Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem 82 (2010), 5219–5226.
24. Wypych, J., Li, M., Guo, A., et al. Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 283 (2008), 16194–16205.
25. Dillon, T.M., Ricci, M.S., Vezina, C., et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 283 (2008), 16206–16215.
26. Yoo, E.M., Wims, L.A., Chan, L.A., Morrison, S.L., Human IgG2 can form covalent dimers. J Immunol 170 (2003), 3134–3138.
27. Yang, J., Goetze, A.M., Flynn, G.C., Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2. Mol Immunol 58 (2014), 108–115.
28. Agarwal, P., Bertozzi, C.R., Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem 26 (2015), 176–192.